<DOC>
	<DOCNO>NCT00434954</DOCNO>
	<brief_summary>This study Germany design compare effect twice-daily exenatide plus metformin twice-daily premixed human insulin aspart plus metformin respect glycemic control , measure HbA1c , combine percentage patient least one treatment-emergent hypoglycemic episode . Patients treat study therapy approximately 26 week .</brief_summary>
	<brief_title>Effect Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin Glycemic Control Hypoglycemia Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Have treat diet exercise stable , maximally tolerate dose immediaterelease extendedrelease metformin , combination metformin ( dosage ) sulfonylurea/meglitinides least 3 month prior study start Have receive thiazolidinediones , alphaglucosidase inhibitor longer 2 week within 3 month prior study start , receive insulin formulation 14 day ( emergency situation ) within 14 day prior study start Have HbA1c 6.5 % 10.0 % , inclusive Have body mass index ( BMI ) 25 kg/m^2 40 kg/m^2 , inclusive Have type 1 diabetes know latent autoimmune diabetes adult Are receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 week prior study start Are receive treatment gastrointestinal disease drug directly affect gastrointestinal motility ( e.g. , metoclopramide , cisapride , chronic macrolide antibiotic ) Have use prescription drug promote weight loss within 3 month prior study start Have receive treatment within 30 day prior study start drug receive regulatory approval indication time study entry Have previously complete withdrawn study study investigate exenatide GLP1 analog</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>